新诊断乳腺癌中的脑转移:一项基于人群的研究
基于美国SEER数据库2010-2013年238726例成人浸润性乳腺癌患者,其中968例(0.41%)在诊断时存在脑转移,占任何部位转移患者的7.56%。激素受体阴性HER2阳性及三阴性亚型诊断时脑转移发生率最高,中位生存分别为21.0个月和6.0个月,三阴性最短为6.0个月。
要点
- 新诊断乳腺癌中脑转移占0.41%,占转移性疾病患者的7.56%。
- HR阴性HER2阳性及三阴性亚型诊断时脑转移发生率最高。
- 脑转移患者中位生存10.0个月,三阴性亚型最短6.0个月。
核心结论
- 本研究提供了乳腺癌诊断时脑转移的发生率和预后的人群基础估计值。
- 研究结果支持考虑对HER2阳性或三阴性亚型且存在颅外转移的患者进行脑部筛查影像检查。
研究设计与样本
- 利用美国国家癌症研究所SEER数据库识别诊断时即存在脑转移的乳腺癌患者,并按亚型、年龄、性别和种族分层。
- 采用多变量逻辑回归和Cox回归分别识别诊断时脑转移的预测因素和与全因死亡率相关的因素。
- 发生率分析纳入2010年至2013年诊断的238726例成人浸润性乳腺癌患者,其诊断时脑转移状态已知。
- 生存分析排除尸检诊断或随访未知的患者,最终纳入231684例患者。
主要发现
- 共识别968例诊断时脑转移患者,占整个队列的0.41%,占任何部位转移患者的7.56%。
- 968例中57例年龄18-40岁,423例41-60岁,425例61-80岁,63例超过80岁;男性10例,女性958例。
- HR阴性HER2阳性亚型发生率最高(整个队列1.1%,任何远处转移患者11.5%),三阴性亚型次之(整个队列0.7%,任何远处转移患者11.4%)。
- 整个脑转移队列中位生存为10.0个月。
- HR阳性HER2阳性亚型中位生存最长(21.0个月),三阴性亚型中位生存最短(6.0个月)。
关键数值与推荐
- 诊断时脑转移发生率:整个队列0.41%,任何部位转移患者7.56%。
- HR阴性HER2阳性亚型发生率:整个队列1.1%,任何远处转移患者11.5%。
- 三阴性亚型发生率:整个队列0.7%,任何远处转移患者11.4%。
- 中位生存:整个脑转移队列10.0个月,HR阳性HER2阳性亚型21.0个月,三阴性亚型6.0个月。
临床怎么用
- 研究结果支持考虑对HER2阳性或三阴性亚型且存在颅外转移的患者进行脑部筛查影像检查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Population-based estimates of the incidence and prognosis of brain metastases at diagnosis of breast cancer are lacking. OBJECTIVE: To characterize the incidence proportions and median survivals of patients with breast cancer and brain metastases at the time of cancer diagnosis. DESIGN, SETTING, AND PARTICIPANTS: Patients with breast cancer and brain metastases at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. Data were stratified by subtype, age, sex, and race. Multivariable logistic and Cox regression were performed to identify predictors of the presence of brain metastases at diagnosis and factors associated with all-cause mortality, respectively. For incidence, we identified a population-based sample of 238 726 adult patients diagnosed as having invasive breast cancer between 2010 and 2013 for whom the presence or absence of brain metastases at diagnosis was known. Patients diagnosed at autopsy or with an unknown follow-up were excluded from the survival analysis, leaving 231 684 patients in this cohort. MAIN OUTCOMES AND MEASURES: Incidence proportion and median survival of patients with brain metastases and newly diagnosed breast cancer. RESULTS: We identified 968 patients with brain metastases at the time of diagnosis of breast cancer, representing 0.41% of the entire cohort and 7.56% of the subset with metastatic disease to any site. A total of 57 were 18 to 40 years old, 423 were 41 to 60 years old, 425 were 61-80 years old, and 63 were older than 80 years. Ten were male and 958 were female. Incidence proportions were highest among patients with hormone receptor (HR)-negative human epidermal growth factor receptor 2 (HER2)-positive (1.1% among entire cohort, 11.5% among patients with metastatic disease to any distant site) and triple-negative (0.7% among entire cohort, 11.4% among patients with metastatic disease to any distant site) subtypes. Median survival among the entire cohort with brain metastases was 10.0 months. Patients with HR-positive HER2-positive subtype displayed the longest median survival (21.0 months); patients with triple-negative subtype had the shortest median survival (6.0 months). CONCLUSIONS AND RELEVANCE: The findings of this study provides population-based estimates of the incidence and prognosis for patients with brain metastases at time of diagnosis of breast cancer. The findings lend support to consideration of screening imaging of the brain for patients with HER2-positive or triple-negative subtypes and extracranial metastases.
引用
- Martin AM, Cagney DN, Catalano PJ, et al. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. JAMA Oncol. 2017. PMID: 28301662. doi:10.1001/jamaoncol.2017.0001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。